Table 2.
Variability expressed as %CV, tabulated either overall or within different groups.
| Biomarker | %CV Overall |
%CV Healthy Control |
%CV GD-Naïve |
%CV GD-Treated |
|---|---|---|---|---|
| Total GSH | 25.5 | 23.2 | 17.2 | 23.6 |
| Ratio GSH/GSSG | 82.6 | 58.6 | 16.7 | 86.7 |
| CAT Activity | 74.0 | 65.9 | 17.4 | 38.4 |
| SOD Activity | 55.7 | 66.4 | 29.7 | 42.7 |
| GPx Activity | 33.3 | 32.2 | 31.9 | 30.9 |
| Protein Carbonyl | 162.3 | 143.9 | 104.7 | 63.6 |
| MDA | 51.1 | 46.3 | 25.6 | 42.6 |
| IL1RA | 81.5 | 41.6 | 38.0 | 66.0 |
| IL-6 | 60.4 | 69.8 | 39.3 | 56.5 |
| IL-8 | 76.3 | 38.1 | 36.5 | 82.2 |
| MCP1 | 51.0 | 50.6 | 36.7 | 54.1 |
| MIP-1a | 164.7 | 81.3 | 205.9 | 173.1 |
| MIP-1b | 138.1 | 87.5 | 60.9 | 84.0 |
| TNFa | 85.9 | 113.7 | 52.7 | 67.1 |
| IL-10 | 701.6 * | 129.4 | 138.5 | 484.4 * |
* When the data for one participant from the GD-treated group was omitted because of apparent outlying measurements, %CV overall, %CV GD-treated were 114.1 and 86.1, respectively.